| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.4 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.4 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.4 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.05 | 0.4 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.4 |
| mRNA | triptolide | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | Imatinib | FIMM | pan-cancer | AAC | -0.15 | 0.4 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |